Nausea News and Research

RSS

Nausea is the sensation of unease and discomfort in the upper stomach and head with an urge to vomit. An attack of nausea is known as a qualm.

NTRILIPIX (fenofibric acid) in combo with Rosuvastatin calcium shows improvement on key lipids for cholesterol management

Data from a new study showed that Abbott's TRILIPIX (fenofibric acid) delayed-release capsules in combination with rosuvastatin calcium met all of the study's primary endpoints.

29 Mar 2009

Dapagliflozin trial results indicate improvement in key glycemic measures in treatment-naive type 2 diabetes

Findings published in Diabetes Care from a 12-week, Phase IIb dose-ranging study showed that dapagliflozin, a novel, selective, sodium glucose co-transporter2 (SGLT2) inhibitor, produced clinically meaningful reductions across all key glycemic measures studied [glycosylated hemoglobin level (HbA1c), fasting plasma glucose (FPG), and postprandial plasma glucose (PPG)] in treatment-naive type 2 diabetes patients, compared to placebo.

29 Mar 2009

Sagent Pharmaceuticals receives FDA approval of Azithromycin for injection

Sagent Pharmaceuticals, Inc. has announced U.S. Food and Drug Administration (FDA) approval of azithromycin for injection, a semi-synthetic, macrolide antibiotic that is used to treat a wide variety of bacterial infections. Sagent will offer azithromycin in a 500 mg vial for intravenous use.

26 Mar 2009

Facial flushing in East Asians who consume alcohol linked to esophageal cancer risks

About one-third of people of Chinese, Japanese and Korean descent have an enzyme deficiency that causes their face to flush when they drink alcohol, a trait that puts them at a higher risk for developing esophageal cancer, according to a study published in the journal PLoS Medicine, Reuters Health reports.

25 Mar 2009

Orexo reports on efficacy study in allergic rhinitis with OX914

Orexo has reported clinical results from an experimental phase IIa safety and efficacy study in allergic rhinitis with OX914, the first compound in its Phosphodiesterase 4 (PDE4) inhibitor program.

24 Mar 2009

Facial flushing after drinking alcohol could be a sign of esophageal cancer

There is growing evidence, say researchers in this week's PLoS Medicine , that people who experience facial flushing after drinking alcohol are at much higher risk of esophageal cancer from alcohol consumption than those who do not.

23 Mar 2009

Alcohol-inducing flushing and esophageal cancer

There is growing evidence, say researchers in this week's PLoS Medicine, that people who experience facial flushing after drinking alcohol are at much higher risk of esophageal cancer from alcohol consumption than those who do not.

23 Mar 2009

Alcohol flush signals increased cancer risk among east Asians

Many people of East Asian descent possess an enzyme deficiency that causes their skin to redden, or flush, when they drink alcohol.

23 Mar 2009

FDA warning on oysters recently harvested from Mississippi area 2C

The U.S. Food and Drug Administration is advising retailers and food service operators not to offer for sale oysters harvested between Feb. 24 and March 17, 2009, from Mississippi Area 2C, located in the Mississippi Sound portion of the Gulf of Mexico near Pass Christian, Miss. Further, consumers are advised not to eat such oysters.

22 Mar 2009

Scientists trial device to treat chemotherapy-related nausea

Trials to test acupressure wrist bands as a drug-free alternative for chemotherapy-related nausea are to take place at the University of Liverpool.

20 Mar 2009

Gleevec reduces risk of cancer returning in patients with life-threatening gastrointestinal stromal tumors

Data published online and in an upcoming print issue of The Lancet show that Gleevec (imatinib mesylate) tablets, when taken after surgery, substantially reduces the rate of recurrence of Kit-positive gastrointestinal stromal tumors (GIST) compared with placebo.

20 Mar 2009

Experimental vaccine shows promise in preventing cytomegalovirus infection

Each year, approximately 8,000 infants in the United States develop severe hearing, mental or movement impairments after becoming infected with cytomegalovirus (CMV), a common virus passed onto them while still in the womb.

19 Mar 2009

Schering-Plough's investigational oral thrombin receptor antagonist meets primary endpoint in a newly published study

Results of a Schering-Plough Corporation Phase II trial of SCH 530348, a novel oral thrombin receptor antagonist (TRA), were published today in The Lancet and demonstrated that the investigational antiplatelet compound met its primary endpoints of safety and tolerability.

12 Mar 2009

Shining light on diabetic retinopathy

A group of scientists in California is trying to develop a cheaper, less invasive way to spot the early stages of retinal damage from diabetic retinopathy, the leading cause of blindness in American adults, before it leads to blindness.

11 Mar 2009

Study of Rituxan (rituximab) in lupus nephritis misses primary endpoint

Genentech, Inc. and Biogen Idec has announced that a Phase III study of Rituxan (rituximab) plus mycophenolate mofetil (MMF) and corticosteroids in patients with lupus nephritis did not meet its primary endpoint of significantly reducing disease activity at 52 weeks.

11 Mar 2009

First 'nano' treatments to target cancer cells

Cancer Research UK scientists have for the first time developed a treatment that transports 'tumour busting' genes selectively to cancer cells, according to a study published online in Cancer Research.

11 Mar 2009

European Commission and US FDA approve intravenous formulation of temozolomide

Schering-Plough Corporation (NYSE:SGP) today announced that the European Commission and the US FDA both approved the intravenous (IV) formulation of temozolomide as an alternative to the already approved oral form of the drug.

5 Mar 2009

Supreme Court rules against Wyeth in pre-emption case

The U.S. Supreme Court on Wednesday ruled 6-3 that consumers harmed by an FDA-approved pharmaceutical product can sue the drugmaker for liability in state courts, the San Francisco Chronicle reports (Egelko, San Francisco Chronicle, 3/5).

5 Mar 2009

Personality factors can influence the development of alcohol dependence

Researchers examined a group of AD individuals with the inactive form of aldehyde dehydrogenase-2 (ALDH2) - persons who would normally have a low incidence of alcoholism because the inactive form of ALDH2 causes flushing, nausea, and headaches. Results indicate that a strong need for novelty and little need for avoiding harm appear to increase the risk of AD.

3 Mar 2009

Chantix side effects no worse for people with history of depression

People with a likely history of depression who take varenicline (Chantix) do not report more severe mood symptoms, medication side effects, or less success quitting smoking compared to people with no history of depression taking this drug.

2 Mar 2009